COVID-19 may enhance risk of thrombosis and hemolysis in the G6PD deficient patients

Aydemir D., Dağlıoğlu G., Ulu A., Kurtaran B., Bozdogan S., İnal T. C., ...More

NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS, vol.40, no.5, pp.505-517, 2021 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 40 Issue: 5
  • Publication Date: 2021
  • Doi Number: 10.1080/15257770.2021.1897457
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, Chemical Abstracts Core, Chimica, EMBASE, MEDLINE
  • Page Numbers: pp.505-517
  • Keywords: COVID-19, glucose-6-phosphate dehydrogenase, hypoxanthine guanine phosphoribosyl transferase, drug therapy, enzyme deficiency
  • Çukurova University Affiliated: Yes


COVID-19 has become a major public health problem since December, 2019 and no highly effective drug has been found until now. Numbers of infected people and deaths by COVID-19 are increasing every day worldwide, therefore self-isolation and protection are highly recommended to prevent the spread of the virus and especially to protect major risk groups such as the elderly population and people with comorbidities including diabetes, hypertension, cancer, cardiovascular diseases and metabolic syndrome. On the other hand, young people without any secondary disease have died by COVID-19 as well. In this study we compared two male patients infected by COVID-19 at the same age and one of them was diagnosed with G6PD deficiency. Both COVID-19 and G6PD deficiency enhance the risk of hemolysis and thrombosis. Serum biochemistry, hemogram and immunological parameters showed that risk of hemolysis and thrombosis may increase in the G6PD deficient patient infected by COVID-19.